To develop a cardiac magnetic resonance (CMR) method for non-invasive estimation of pulmonary vascular resistance (PVR).
Introduction
Pulmonary vascular resistance (PVR) has important implications in the diagnostic evaluation and prognosis of patients with pulmonary hypertension (PH). 1, 2 Currently, quantification of PVR requires invasive right heart catheterization (RHC). An accurate non-invasive method for measurement of PVR would be helpful to eliminate the discomfort, radiation exposure, and small but real risk of morbidity and mortality associated with RHC. 3 Doppler echocardiography has become routine in the non-invasive estimation of systolic pulmonary arterial pressure (PAP), 1 but is not widely accepted for estimation of PVR because of inconclusive and conflicting data. 4 -9 Cardiac magnetic resonance (CMR) has been proposed as an alternative to echocardiography in assessing pulmonary circulation haemodynamics. 10 -14 Because of its ability to accurately evaluate both right ventricular (RV) and pulmonary artery (PA) anatomy and function, CMR offers the potential for PVR quantification. Preliminary studies have shown significant correlations between several CMR-derived parameters and RHC-quantified PVR. 15 -20 We hypothesized that a model based on CMR could allow for non-invasive estimation of absolute PVR values.
Methods Population
Consecutive patients clinically referred for the evaluation of known or suspected chronic PH who underwent RHC and CMR on the same day were included in the study. Patients with intra-cardiac shunts were excluded. The underlying diseases responsible for the established or presumed diagnosis of PH were determined and categorized according to the recently revised classification of PH. 21 The Institutional Review
Board approved the study with a waiver of informed consent and all individuals consented for the procedures.
Cardiac magnetic resonance
Cardiac magnetic resonance studies were performed with either 1.5 Tesla (Magnetom Sonata w , Siemens Medical Solutions) or 3.0 Tesla (Achieva w , Philips Medical Systems) magnets, using dedicated surface coils and retrospective electrocardiographic gating. Images were obtained during end-expiratory breath holds. For cine imaging of the RV, a steady-state free precession sequence was used to acquire 10 -15 contiguous short-axis slices covering both ventricles from base to apex, and reconstructed into 25 cardiac phases each for the evaluation of ventricular volumes and function. Typical imaging parameters included: repetition time/echo time: 3.2 -3.9/1.6-2 ms; flip angle: 45 -908; slice thickness: 6 mm; inter-slice gap: 4 mm; in-plane spatial resolution: 1.5 -2 mm; temporal resolution: 33 -45 ms. Flow imaging was performed perpendicular to the main PA with a velocity-encoded gradient echo sequence and an upper velocity limit of 100 cm/s (with further increases if any signal aliasing). For this purpose, two double-oblique orthogonal views oriented along the main axis of the PA trunk were acquired with a standard steady-state free precession cine sequence and used as the reference to prescribe a plane truly perpendicular to the main PA for the acquisition of phasecontrast images. Care was taken to ensure that the imaging plane remained between the pulmonary valve and PA bifurcation throughout the cardiac cycle. In addition, aortic velocity and left ventricular cardiac output were systematically measured to rule out intra-cardiac shunts. The following typical imaging parameters were applied: repetition time/ echo time: 5.9 -7.5/3.1-3.6 ms; number of excitations: 1; slice thickness: 6 mm; in-plane resolution: 1.5 -3 mm; reconstructed cardiac phases: 20; temporal resolution: 55 -105 ms.
Images were analysed using specialized software (Argus w , Siemens Medical Solutions, Erlangen, Germany or Extended MR Workspace w , Philips Medical Systems, Best, Netherlands). On cine images, enddiastolic and end-systolic frames were selected based on visual assessment of largest and smallest ventricular volumes, respectively, and on the opening or closing of atrioventricular and semilunar valves. Biventricular endocardial contours were manually traced in end-diastole and end-systole, and Simpson's method was used to automatically calculate end-diastolic volumes, end-systolic volumes, and ejection fractions. Right ventricular trabeculations were included within the blood pool. Similarly, the inner contours of the main PA cross-section were outlined in each cardiac phase and, through integration of PA areas and flow, the following parameters were quantified: peak velocity, average velocity during the complete cardiac cycle, minimum and maximum areas, and PA net forward volume. No phase-offset correction was performed. Pulmonary artery pulsatility was calculated as (maximal PA area 2 minimal PA area)/minimal PA area × 100. 18 Biventricular volumes and PA areas were adjusted by body surface area to account for differences in patients' size.
Right heart catheterization
Right heart catheterization was performed using a Swan-Ganz catheter introduced via femoral or internal jugular vein approach following standard methods. Haemodynamic measurements included mean right atrial pressure, systolic, mean and diastolic PAP, pulmonary capillary wedge pressure, and RV cardiac output (thermodilution method). Pulmonary vascular resistance was calculated as the difference between mean PAP and capillary wedge pressures divided by the RV cardiac output. The diagnosis of PH was established when mean PAP was .25 mmHg, and increased PVR was defined as .3 WU. 1 
Statistical analysis
Categorical values were expressed as absolute number (percentage), and continuous variables as median (inter-quartile range). The study population was randomly divided into a derivation cohort (80% of patients) and a validation cohort (20% of patients) using a free-available software (Research randomizer w ). 22 The derivation cohort was used to develop the model for the estimation of PVR and the validity of the model was tested in the validation cohort. First, direction and strength of univariate associations between CMR-derived parameters and invasively quantified PVR were assessed using Spearman correlation coefficients. Scatter plots were evaluated to determine association type (e.g. linear, exponential) and pertinent variable transformations were performed accordingly. Subsequently, based on theoretical principles and the strength of association with PVR, six variables were selected and combined to create all possible models using a macro for SPSS w . 23 The best model was obtained based on statistical criteria and physiological plausibility. Statistically, a model was considered better fitting if its Mallows' Cp statistic, Akaike and Bayesian information criteria were smaller with a similar adjusted R 2 than the rest of possible statistical models. Fulfilment of homoscedasticity, independence of observations, and log-linear relation of the multivariate model was checked in the final model by assessment of the distribution of residuals. Diagnostic accuracy of the model for PVR estimation in the derivation cohort was assessed using Spearman correlation, BlandAltman analysis, and receiver operator characteristics (ROC) curve. A cut-off value with balanced sensitivity and specificity to diagnose increased PVR was derived from the ROC curve. Validity of the model was assessed in the validation cohort using the same tests. Additionally, Kappa coefficient was calculated to evaluate the agreement between the model and RHC to diagnose increased PVR. The quality of the PVR estimation was individually assessed in the validation cohort by examining the estimate value and the standard error of estimate, compared with the invasive PVR value. Subsequently, the derivation and validation cohorts were pooled together and the accuracy of the CMR model was compared in the following prespecified subgroups: men vs. women, age below or equal and above the median age, pulmonary arterial hypertension (PAH) vs. other PH aetiologies, and severely vs. non-severely increased PVR (defined as PVR ≤ or .8 WU, respectively). 7 Comparisons between r coefficients in two different subgroups were performed using Fisher's Z transformation. To evaluate the intra-observer and inter-observer reproducibility of the method, 10 CMR studies were measured twice by the same investigator and by two different investigators and intra-class correlation coefficient for absolute agreement and the mean value and standard deviation of differences were calculated. All tests were two-tailed and a P value ,0.05 was considered statistically significant. Statistical analyses were performed with SPSS w (version 15.0).
Results
A total of 100 consecutive patients were identified (after excluding 4 patients with intra-cardiac shunts) and randomly classified into the derivation (n ¼ 80) and validation (n ¼ 20) cohorts. Ninety-eight studies were performed with the 1.5-Tesla Siemens scanner and two studies (both in the derivation cohort) with the 3-Tesla Philips scanner. Clinical, RHC, and CMR data for the study population are
Non-invasive estimation of PVR with CMR summarized in Table 1 . Median age was 52 years and 73% were female. A diagnosis of PH was established by RHC in 79% of patients. Median PVR was 4.7 with a range from 0.4 to 16.4 WU. Baseline characteristics were balanced between cohorts. There were no statistically significant differences except for the PA net forward volume that was lower in the validation cohort. Correlations between CMR measurements and RHC PVR are shown in Table 2 . PA average velocity, PA minimal area, PA net forward volume, RV cardiac output, RVEF, and RV end-systolic volume were selected and combined to create all possible models to estimate PVR. Scatter plots of the two variables with highest correlation coefficients, RVEF, and PA average velocity are shown in Figure 1 . The model combining natural logtransformed PA average velocity and RVEF showed the best statistical performance when compared with all other possible models, and was considered theoretically plausible. beta coefficients were 20.3 and 20.54 for RVEF and Ln PA velocity, respectively. In the derivation cohort (n ¼ 80), estimated PVR using the noninvasive model strongly correlated with invasive PVR (r ¼ 0.83; P , 0.001; Figure 2A ). On Bland-Altman analysis, the mean bias was 0.095 and the 95% confidence interval (CI) ranged from 24.71 to 4.89 WU ( Figure 2B) . Agreement was better at lower than higher PVR values. The area under the ROC curve for CMR-model to detect increased PVR was 0.96; 95% CI: 0.92-0.99 ( Figure 2C ). An optimal cut-off value of 4.2 provided the best balanced sensitivity (92.5%) and specificity (85.2%).
On the validation group, the correlation between estimated PVR and invasive PVR remained high (r ¼ 0.84; P , 0.001, Figure 3A) . Figure 3B) . The area under the ROC curve for estimated PVR to detect increased PVR was 0.97; 95% CI: 0.89-1.00 ( Figure 3C ). Using the cut-off point of 4.2, the model correctly classified 18 (90%) of patients, with a Kappa coefficient of 0.78; P , 0.001. Table 3 shows the invasive PVR, the non-invasively estimated PVR, and the standard error of the estimation for all 20 patients in the validation cohort.
Subgroup
Discussion
Our results suggest that non-invasive estimation of PVR using CMR is feasible and the model derived allowed the detection of increased PVR with high accuracy when compared with RHC. Pulmonary vascular resistance is important in the diagnosis, management, and prognosis of patients with PH.
1,2 While diagnosis of PH is currently based on PAP, a more consistent prognostic value for PVR has been reported, at least in idiopathic PH. 2 In addition, in advanced stages of chronic PH, as RV failure progresses, PAP may decrease while PVR continues to increase. Prior studies have explored the potential of CMR for the quantification of PAP using a variety of parameters, but preliminary promising results have not been confirmed when validated in external populations. 25 Also, several studies, all including smaller sample sizes than the current investigation, have reported correlations of CMR-derived indices with PVR. 15 -20 Mousseaux et al. 17 reported that the ratio of maximal change in flow rate during ejection to acceleration volume could serve to identify patients with PVR ≥6 WU. Other prior investigations also combined invasively determined PAP and simultaneous phase-contrast imaging to quantify PVR. 26, 27 However, to the best of our knowledge, there are no validated methods to quantify absolute PVR values with CMR in a completely non-invasive fashion. We found that the goodness of fit for PVR estimation of a simplified model that included PA average velocity and RVEF was similar to more complex models, including multiple additional variables. An additional advantage of this method is that RVEF and PA average velocity are easily quantifiable without the use of contrast agents. At the present time, we consider that this non-invasive method could be useful as a first step in the diagnosis of suspected PH. Those patients with positive results (estimated PVR .4.2) should still undergo invasive catheterization to confirm diagnosis prior to the initiation of specific therapy. Pulmonary artery velocity was the parameter that had the strongest univariate correlation with PVR and the highest weight in the predictive model (almost double than RVEF). From a pathophysiologic perspective, PA velocity has the advantage of being a dynamic parameter with the potential to track PVR changes (S. Dellegrottaglie, unpublished data from our laboratory). The presence of low PA velocities in patients with PH has been widely described. 10, 28 There are several potential explanations for this finding. Patients with PH may present PA dilatation and, for any given flow and PAP, as the PA dilates the velocity decreases. 29 PH may also be accompanied by the presence of systolic retrograde flow in the PA that can contribute in reduction of average velocity. 10, 28 Moreover, as PVR increases, blood transit through the pulmonary tree is hampered, 30 leading to slowing of blood flow. One additional advantage of averaging velocity from the complete PA cross-section throughout the cardiac cycle includes the lack of assumption of a uniform PA flow profile.
Other techniques such as Doppler ultrasound and catheter-tip velocity transducer can only determine velocity at a single point within the cross-section. In a previous study of our group that explored simple correlations between flow parameters and pulmonary hemodynamics, PA average velocity demonstrated the strongest correlation with indexed PVR. 19 In our current study, we confirmed this association and identified its curvilinear nature: at advanced stages, PVR continues to increase with little reduction in PA average velocity, maybe because the PA cannot distend further. Right ventricular ejection fraction also showed a good correlation with PVR, indicating that the degree of RV dysfunction is largely a reflection of the severity and chronicity of PH. The addition of RVEF into the model may improve its diagnostic accuracy in late phases of the disease, when PA average velocity is in its plateau. In subgroup analyses, the model performed similarly irrespective of age, gender, and PH aetiology, but we observed lower accuracy with PVR underestimation in patients with severely increased resistances. The higher the PVR, the poorer the agreement between invasive and estimated PVR, could also be noticed in the Bland-Altman analysis ( Figure 2B ). As the model is based on a constant of 19 from which the RVEF and PA velocity products are subtracted, our method cannot predict a PVR value .19 WU. Therefore, our model would probably not be able to detect changes within ranges of very severe PVR elevation, although reversibility to moderate or mildly increased PVR could theoretically be detected.
The main limitation of our study is that RHC and CMR were not performed simultaneously; so some spontaneous variation in PVR may have occurred between tests. 31 We tried to overcome this limitation by studying only patients who underwent both procedures within the same day. Whereas invasive measurements were obtained during free-breathing, CMR was performed during breath-hold, which might have caused small changes in pulmonary blood velocity and cardiac output. 32 We validated our CMR method with RHC, the current gold standard for PVR quantification. However, it must be acknowledged that RHC also has limitations, including inaccurate wedge pressure quantification due to vessel pruning or imprecise measurement of cardiac output by thermodilution in the presence of significant tricuspid regurgitation. Invasive measures were obtained using fluid-filled catheters rather than manometer-tipped high-fidelity catheters, which could result in overestimation of peak systolic pressure; however, the expected error in PVR quantification is considered to be very small. 33 The temporal resolution used for phasecontrast images tends to under-estimate cardiac output, as shown in Table 1 . We studied patients with chronic PH; so our conclusions may not be extrapolated to acute PH. Our model was developed and tested in a population with 30% of patients with severe PH; therefore, the application of this model to a population with significantly higher proportion of patients with severely increased PVR may require model recalibration. The population included in the study is heterogeneous regarding aetiology and range of PVR severity. Although this might have detrimentally affected the performance of our model, it is representative of typical referrals to RHC for PH evaluation. Specifically, our data cannot be extrapolated to patients with shunts since those patients were excluded of our study. Finally, the study sample size, especially the validation cohort size, was relatively small and originated from a single centre. A larger validation study and external validation, ideally in a multicenter study, should be performed to confirm the accuracy of the model. In conclusion, completely non-invasive estimation of PVR with CMR is feasible with acceptable limits of agreement and high accuracy to detect increased PVR. This novel method could have important clinical applications such as being an initial step in the diagnosis of PH, and potentially evaluating serial changes related to disease course or therapeutic interventions. 
